Oncolytics Completes March 31 Nevada Domestication, Moves Headquarters to San Diego
Oncolytics Biotech completed its domestication from Alberta to Nevada, effective March 31, 2026, with Calgary retained as an office and San Diego designated as new headquarters. The domicile change grants streamlined regulatory filings, enhanced operational efficiency and improved access to U.S. capital markets, while its Nasdaq trading continues under ticker ONCY with new CUSIP 68237V103 and ISIN US68237V1035.
1. Jurisdiction Change Completed
On April 1, 2026, Oncolytics Biotech finalized its change in incorporation from the Province of Alberta in Canada to the State of Nevada. The Company first continued its existence to the Province of British Columbia on March 17, 2026, before filing effective March 31, 2026, with the Nevada Secretary of State. Calgary remains an office location, while San Diego becomes the new corporate headquarters.
2. Expected Benefits of U.S. Domicile
The shift to a U.S. domestic issuer status is designed to streamline the regulatory framework, enhance operational efficiency and improve access to U.S. capital markets. No longer qualifying as a foreign private issuer under U.S. securities laws, the Company anticipates reduced compliance complexity and closer alignment with its predominantly U.S.-based investor and management base.
3. Trading and Identifier Updates
Oncolytics’ common stock will continue trading on the Nasdaq under ticker ONCY without interruption. Effective immediately, the CUSIP for the common stock is 68237V103 and the ISIN is US68237V1035, replacing prior identifiers while maintaining the existing trading and listing structure.